-
1
-
-
0032511580
-
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
-
UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317 (1998) 703-713
-
(1998)
BMJ
, vol.317
, pp. 703-713
-
-
UK Prospective Diabetes Study Group1
-
2
-
-
3142781955
-
Prevention of type 2 diabetes mellitus through inhibition of the rennin-angiotensin system
-
Scheen A.J. Prevention of type 2 diabetes mellitus through inhibition of the rennin-angiotensin system. Drugs 64 (2004) 2537-2565
-
(2004)
Drugs
, vol.64
, pp. 2537-2565
-
-
Scheen, A.J.1
-
3
-
-
0037160968
-
Cardiovascular morbidity and mortality in the Losartan intervention for endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol
-
Dahlof B., et al. Cardiovascular morbidity and mortality in the Losartan intervention for endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 359 (2002) 995-1003
-
(2002)
Lancet
, vol.359
, pp. 995-1003
-
-
Dahlof, B.1
-
4
-
-
18544376399
-
Risk of new-onset diabetes in the Losartan intervention for endpoint reduction in hypertension study
-
Lindholm L.H., et al. Risk of new-onset diabetes in the Losartan intervention for endpoint reduction in hypertension study. J. Hypertens. 20 (2002) 1879-1886
-
(2002)
J. Hypertens.
, vol.20
, pp. 1879-1886
-
-
Lindholm, L.H.1
-
5
-
-
0042410539
-
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-overall programme
-
Pfeffer M.A., et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-overall programme. Lancet 362 (2003) 759-766
-
(2003)
Lancet
, vol.362
, pp. 759-766
-
-
Pfeffer, M.A.1
-
6
-
-
2942635317
-
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial
-
Julius S., et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 363 (2004) 2022-2031
-
(2004)
Lancet
, vol.363
, pp. 2022-2031
-
-
Julius, S.1
-
7
-
-
1542547460
-
Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity
-
Benson S.C., Pershadsingh H.A., Ho C.I., Chittiboyina A., Desai P., Pravenec M., et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 43 (2004) 993-1002
-
(2004)
Hypertension
, vol.43
, pp. 993-1002
-
-
Benson, S.C.1
Pershadsingh, H.A.2
Ho, C.I.3
Chittiboyina, A.4
Desai, P.5
Pravenec, M.6
-
8
-
-
10344249378
-
Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the rennin-angiotensin system
-
Kurtz T.W., and Pravenec M. Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the rennin-angiotensin system. J. Hypertens. 22 (2004) 2253-2261
-
(2004)
J. Hypertens.
, vol.22
, pp. 2253-2261
-
-
Kurtz, T.W.1
Pravenec, M.2
-
9
-
-
0030994947
-
The homeostasis model in the San Antonio Heart Study
-
Haffner S.M., Miettinen H., and Stern M.P. The homeostasis model in the San Antonio Heart Study. Diabetes Care 20 (1997) 1087-1092
-
(1997)
Diabetes Care
, vol.20
, pp. 1087-1092
-
-
Haffner, S.M.1
Miettinen, H.2
Stern, M.P.3
-
10
-
-
33646590317
-
Serum adiponectin is associated with fasting serum C-peptide in non-obese diabetic patients
-
Furuta M., Tamai M., Hanabusa T., Yamamoto Y., Nanjo K., and Sanke T. Serum adiponectin is associated with fasting serum C-peptide in non-obese diabetic patients. Diab. Res. Clin. Pract. 72 (2006) 302-307
-
(2006)
Diab. Res. Clin. Pract.
, vol.72
, pp. 302-307
-
-
Furuta, M.1
Tamai, M.2
Hanabusa, T.3
Yamamoto, Y.4
Nanjo, K.5
Sanke, T.6
-
11
-
-
1842537144
-
Insulin-sensitizing effects of telmisartan; Implications for treating insulin-resistant hypertension and cardiovascular disease
-
Kurtz T.W. Insulin-sensitizing effects of telmisartan; Implications for treating insulin-resistant hypertension and cardiovascular disease. Diabetes Care 27 (2004) 1015
-
(2004)
Diabetes Care
, vol.27
, pp. 1015
-
-
Kurtz, T.W.1
-
12
-
-
14644444519
-
Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes
-
Miura Y., Yamamoto N., Tsunekawa S., Taguchi S., Eguchi Y., Ozaki N., et al. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes. Diabetes Care 28 (2005) 757-758
-
(2005)
Diabetes Care
, vol.28
, pp. 757-758
-
-
Miura, Y.1
Yamamoto, N.2
Tsunekawa, S.3
Taguchi, S.4
Eguchi, Y.5
Ozaki, N.6
-
13
-
-
12844262135
-
Possible beneficial effect of telmisartan on glycemic control in diabetic subjects
-
Honjo S., Nishi Y., Wada Y., Hamamoto Y., and Koshiyama H. Possible beneficial effect of telmisartan on glycemic control in diabetic subjects. Diabetes Care 28 (2005) 498
-
(2005)
Diabetes Care
, vol.28
, pp. 498
-
-
Honjo, S.1
Nishi, Y.2
Wada, Y.3
Hamamoto, Y.4
Koshiyama, H.5
-
14
-
-
52949122524
-
The AT1-receptor blocker telmisartan is a partial PPAR-alpha agonist
-
Clementz M., Frost N., Schupp M., Unger T., Staels B., and Kintscher U. The AT1-receptor blocker telmisartan is a partial PPAR-alpha agonist. Hypertension 46 (2005) 889
-
(2005)
Hypertension
, vol.46
, pp. 889
-
-
Clementz, M.1
Frost, N.2
Schupp, M.3
Unger, T.4
Staels, B.5
Kintscher, U.6
-
15
-
-
0035989093
-
Acute effects of valsartan on insulin sensitivity in obese, non-hypertensive subjects with and without type 2 diabetes
-
Luzio S.D., Dunseath G., and Owens D.R. Acute effects of valsartan on insulin sensitivity in obese, non-hypertensive subjects with and without type 2 diabetes. Horm. Metab. Res. 34 (2002) 271-274
-
(2002)
Horm. Metab. Res.
, vol.34
, pp. 271-274
-
-
Luzio, S.D.1
Dunseath, G.2
Owens, D.R.3
-
16
-
-
3042732493
-
Candesartan, an angiotensin II receptor blocker, improves left ventricular hypertrophy and insulin resistance
-
Anan F., Takahashi N., Ooie T., Hara M., Yoshimatsu H., and Saikawa T. Candesartan, an angiotensin II receptor blocker, improves left ventricular hypertrophy and insulin resistance. Metabolism 53 (2004) 777-781
-
(2004)
Metabolism
, vol.53
, pp. 777-781
-
-
Anan, F.1
Takahashi, N.2
Ooie, T.3
Hara, M.4
Yoshimatsu, H.5
Saikawa, T.6
-
17
-
-
2442451618
-
Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-γactivity
-
Schupp M., Janke J., Clasen R., Unger T., and Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-γactivity. Circulation 109 (2004) 2054-2057
-
(2004)
Circulation
, vol.109
, pp. 2054-2057
-
-
Schupp, M.1
Janke, J.2
Clasen, R.3
Unger, T.4
Kintscher, U.5
-
18
-
-
0842313004
-
Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients
-
Bajaj M., Suraamornkul S., Piper P., Hardies L.J., Glass L., Cersosimo E., et al. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J. Clin. Endocrinol. Metab. 89 (2004) 200-206
-
(2004)
J. Clin. Endocrinol. Metab.
, vol.89
, pp. 200-206
-
-
Bajaj, M.1
Suraamornkul, S.2
Piper, P.3
Hardies, L.J.4
Glass, L.5
Cersosimo, E.6
-
19
-
-
0036789137
-
The effect of thiazolidinediones on plasma adiponectin levels in normal, obese and type 2 diabetic subjects
-
Yu J.G., Javorschi S., Hevener A.L., Kruszynska Y.T., Norman R.A., Sinha M., et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese and type 2 diabetic subjects. Diabetes 51 (2002) 2968-2974
-
(2002)
Diabetes
, vol.51
, pp. 2968-2974
-
-
Yu, J.G.1
Javorschi, S.2
Hevener, A.L.3
Kruszynska, Y.T.4
Norman, R.A.5
Sinha, M.6
-
20
-
-
33644781780
-
Angiotensin II type receptor blockade improves β-cell function and glucose tolerance in a mouse model of type 2 diabetes
-
Chu K.Y., Lau T., Carlsson P.-O., and Leung P.S. Angiotensin II type receptor blockade improves β-cell function and glucose tolerance in a mouse model of type 2 diabetes. Diabetes 55 (2006) 367-374
-
(2006)
Diabetes
, vol.55
, pp. 367-374
-
-
Chu, K.Y.1
Lau, T.2
Carlsson, P.-O.3
Leung, P.S.4
-
21
-
-
6344258928
-
An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes
-
Fujimoto M., Masuzaki H., Tanaka T., Yasue S., Tomita T., Okazawa K., et al. An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes. FEBS Lett. 576 (2004) 492-497
-
(2004)
FEBS Lett.
, vol.576
, pp. 492-497
-
-
Fujimoto, M.1
Masuzaki, H.2
Tanaka, T.3
Yasue, S.4
Tomita, T.5
Okazawa, K.6
-
22
-
-
12444273748
-
Distinct properties and advantages of a novel peroxisome proliferator-activated protein (γ) selective modulator
-
Berger J.P., Petro A.E., Macnaul K.L., Kelly L.J., Zhang B.B., Richards K., et al. Distinct properties and advantages of a novel peroxisome proliferator-activated protein (γ) selective modulator. Mol. Endocrinol. 17 (2003) 662-676
-
(2003)
Mol. Endocrinol.
, vol.17
, pp. 662-676
-
-
Berger, J.P.1
Petro, A.E.2
Macnaul, K.L.3
Kelly, L.J.4
Zhang, B.B.5
Richards, K.6
-
23
-
-
33644672013
-
Molecular characterization of new selective peroxisome proliferator-activated receptor γ modulators with angiotensin receptor blocking activity
-
Schupp M., Clemenz M., Gineste R., Witt H., Janke J., Helleboid S., et al. Molecular characterization of new selective peroxisome proliferator-activated receptor γ modulators with angiotensin receptor blocking activity. Diabetes 54 (2005) 3442-3452
-
(2005)
Diabetes
, vol.54
, pp. 3442-3452
-
-
Schupp, M.1
Clemenz, M.2
Gineste, R.3
Witt, H.4
Janke, J.5
Helleboid, S.6
-
24
-
-
33646148948
-
Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis
-
Sugimoto K., Qi N.R., Kazdova L., Pravenec M., Ogihara T., and Kurtz T.W. Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension 47 (2006) 822-823
-
(2006)
Hypertension
, vol.47
, pp. 822-823
-
-
Sugimoto, K.1
Qi, N.R.2
Kazdova, L.3
Pravenec, M.4
Ogihara, T.5
Kurtz, T.W.6
-
25
-
-
0032505096
-
Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ
-
Nolte R.T., Wisely G.B., Westin S., Cobb J.E., Lambert M.H., Kurokawa R., et al. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ. Nature 395 (1998) 137-143
-
(1998)
Nature
, vol.395
, pp. 137-143
-
-
Nolte, R.T.1
Wisely, G.B.2
Westin, S.3
Cobb, J.E.4
Lambert, M.H.5
Kurokawa, R.6
|